問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Veterans General Hosptial (在職)

Division of Infectious Disease

Division of General Internal Medicine

更新時間：2023-09-19

陳垚生
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

5Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳垚生

List

42Cases

2010-11-15 - 2012-06-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2018-08-01 - 2023-01-31

Phase III

Completed
A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERIA PRODUCING METALLO-Β-LACTAMASE (MBL)

  • Condition/Disease

    SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERIA PRODUCING METALLO -Β-LACTAMASE (MBL)

  • Test Drug

    PF-06947387 (Aztreonam –Avibactam)

Participate Sites
3Sites

Not yet recruiting3Sites

2018-05-01 - 2023-05-17

Phase III

Completed
A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS

  • Condition/Disease

    SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS

  • Test Drug

    PF-06947387 (Aztreonam –Avibactam)

Participate Sites
7Sites

Not yet recruiting6Sites

Terminated1Sites

2019-08-22 - 2021-06-16

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2009-11-01 - 2010-01-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2016-08-01 - 2018-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2024-12-01 - 2025-11-30

Phase III

Completed
A Phase 3, Randomized, Observer‑blind, Active‑control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA‑1083 (SARS‑CoV‑2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age

  • Condition/Disease

    SARS‑CoV‑2 and Influenza

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2022-11-21 - 2023-12-20

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2024-09-01 - 2026-09-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2004-07-01 - 2005-12-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB